1. Aviado DM, Dettelbach HR. Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication. Angiology. 1984;35(7):407–17.
2. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery. 1991;110(2):192–8.
3. Wen WX, Lee SY, Siang R, Koh RY. Repurposing pentoxifylline for the treatment of fibrosis: an overview. Adv Ther. 2017;34(6):1245–69.
4. De Sanctis MT, Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, Incandela L, Bucci M, Geroulakos G, Ramaswami G, Vasdekis S, Agus G, Bavera P, Ippolito E. Treatment of intermittent claudication with pentoxifylline: a 12-month, randomized trial–walking distance and microcirculation. Angiology. 2002;53(Suppl 1):S7-12.
5. Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. 1984;4(6):297–307.